Publications by authors named "B Terrier"
Erratum for Barbosa Bomfim et al., "CGRP inhibits SARS-CoV-2 infection of bronchial epithelial cells, and its pulmonary levels correlate with viral clearance in critical COVID-19 patients".
Caio César Barbosa Bomfim Hugo Génin Andréa Cottoignies-Callamarte Sarah Gallois-Montbrun Emilie Murigneux Benjamin Terrier
J Virol
December 2024
Background: The PEXIVAS (Plasma exchange and glucocorticoids in severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis) trial showed that a reduced-dose glucocorticoid regimen (redGC) was non-inferior to a standard-dose regimen (standGC) with respect to death or end-stage kidney disease (ESKD) in patients with ANCA-associated vasculitis (AAV). However, the primary endpoint did not include disease progression or relapse, cyclophosphamide was the main induction therapy and rituximab (RTX)-treated patients tended to have a higher risk of death or ESKD with redGC. We aimed to evaluate the real-world use of redGC.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the effectiveness of combining glucocorticoids (GCs) with cyclophosphamide (CYC) for treating patients with poor-prognosis eosinophilic granulomatosis with polyangiitis (EGPA) compared to using GCs alone.
- Data from a European multicenter database were analyzed, involving 209 patients and focusing on relapse rates and other related outcomes over 12 to 24 months.
- Results indicated that adding CYC significantly reduced the risk of relapse and related complications compared to GCs alone, suggesting a beneficial role for CYC in the treatment of poor-prognosis EGPA.
Article Synopsis
- * Using a cohort of over 3,600 participants, researchers measured levels of specific antibodies and assessed SARS-CoV-2 infection outcomes over the next six months.
- * Results showed that higher anti-Spike IgG antibody levels correlated with reduced infection risk in the control group, but this was not the case for individuals in specific patient populations.